Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer

NCT06520683 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

180

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer
Microsatellite Instability High

Interventions

DRUG: Tislelizumab
DRUG: Adjuvant chemotherapy

Sponsor

Sun Yat-sen University

Collaborators

[object Object]